pharmacogenomic innovative solutions limited
pharmacogenomic innovative solutions limited Company Information
Company Number
06242578
Next Accounts
Mar 2025
Shareholders
cytopathfinder inc.
Group Structure
View All
Industry
Management consultancy activities (other than financial management)
Registered Address
grove house, grove house, manor close, high wycombe, buckinghamshire, HP10 8HZ
Website
pgxis.compharmacogenomic innovative solutions limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED at £0 based on a Turnover of £0 and 0.49x industry multiple (adjusted for size and gross margin).
pharmacogenomic innovative solutions limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED at £0 based on an EBITDA of £-1k and a 4.24x industry multiple (adjusted for size and gross margin).
pharmacogenomic innovative solutions limited Estimated Valuation
Pomanda estimates the enterprise value of PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED at £0 based on Net Assets of £-294 and 2.61x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pharmacogenomic Innovative Solutions Limited Overview
Pharmacogenomic Innovative Solutions Limited is a dissolved company that was located in high wycombe, HP10 8HZ with a Companies House number of 06242578. It operated in the management consultancy activities other than financial management sector, SIC Code 70229. Founded in May 2007, it's largest shareholder was cytopathfinder inc. with a 100% stake. The last turnover for Pharmacogenomic Innovative Solutions Limited was estimated at £0.
Upgrade for unlimited company reports & a free credit check
Pharmacogenomic Innovative Solutions Limited Health Check
Pomanda's financial health check has awarded Pharmacogenomic Innovative Solutions Limited a 1 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 1 areas for improvement. Company Health Check FAQs
1 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 46 weeks, this is more cash available to meet short term requirements (27 weeks)
- - Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 112.2%, this is a higher level of debt than the average (56.7%)
- - Pharmacogenomic Innovative Solutions Limited
- - Industry AVG
PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED financials
Pharmacogenomic Innovative Solutions Limited's latest turnover from May 2020 is estimated at 0 and the company has net assets of -£294. According to their latest financial statements, we estimate that Pharmacogenomic Innovative Solutions Limited has no employees and maintains cash reserves of £2.4 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| May 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||||
| Other Income Or Grants | ||||||||||||
| Cost Of Sales | ||||||||||||
| Gross Profit | ||||||||||||
| Admin Expenses | ||||||||||||
| Operating Profit | ||||||||||||
| Interest Payable | ||||||||||||
| Interest Receivable | ||||||||||||
| Pre-Tax Profit | ||||||||||||
| Tax | ||||||||||||
| Profit After Tax | ||||||||||||
| Dividends Paid | ||||||||||||
| Retained Profit | ||||||||||||
| Employee Costs | ||||||||||||
| Number Of Employees | ||||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| May 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 196 | 567 | 780 | 863 | 31 | 606 | 1,790 | 1,707 | ||||
| Intangible Assets | ||||||||||||
| Investments & Other | 7,172 | 27,528 | ||||||||||
| Debtors (Due After 1 year) | 84,524 | |||||||||||
| Total Fixed Assets | 7,172 | 27,724 | 85,091 | 780 | 863 | 31 | 606 | 1,790 | 1,707 | |||
| Stock & work in progress | ||||||||||||
| Trade Debtors | 145,000 | 3,888 | 4,661 | 40,259 | 45,597 | 13,140 | 164,804 | 312,491 | 12,578 | |||
| Group Debtors | ||||||||||||
| Misc Debtors | ||||||||||||
| Cash | 2,406 | 3,444 | 136,058 | 105,655 | 3,538 | 23,412 | 55,637 | 12,536 | 40,616 | 9,103 | 33,401 | 97,265 |
| misc current assets | ||||||||||||
| total current assets | 2,406 | 3,444 | 281,058 | 105,655 | 7,426 | 28,073 | 95,896 | 58,133 | 53,756 | 173,907 | 345,892 | 109,843 |
| total assets | 2,406 | 3,444 | 281,058 | 112,827 | 35,150 | 113,164 | 96,676 | 58,996 | 53,787 | 174,513 | 347,682 | 111,550 |
| Bank overdraft | ||||||||||||
| Bank loan | ||||||||||||
| Trade Creditors | 2,700 | 1,800 | 2,040 | 36,530 | 119,528 | 142,655 | 17,131 | 20,978 | 383,237 | 13,362 | 12,987 | |
| Group/Directors Accounts | ||||||||||||
| other short term finances | ||||||||||||
| hp & lease commitments | ||||||||||||
| other current liabilities | 2,700 | |||||||||||
| total current liabilities | 2,700 | 2,700 | 1,800 | 2,040 | 36,530 | 119,528 | 142,655 | 17,131 | 20,978 | 383,237 | 13,362 | 12,987 |
| loans | 365,868 | 360,915 | 360,928 | |||||||||
| hp & lease commitments | ||||||||||||
| Accruals and Deferred Income | ||||||||||||
| other liabilities | 360,915 | 857,405 | 461,036 | 800,241 | 641,675 | |||||||
| provisions | ||||||||||||
| total long term liabilities | 365,868 | 360,915 | 360,928 | 360,915 | 857,405 | 461,036 | 800,241 | 641,675 | ||||
| total liabilities | 2,700 | 2,700 | 1,800 | 2,040 | 402,398 | 480,443 | 503,583 | 378,046 | 878,383 | 844,273 | 813,603 | 654,662 |
| net assets | -294 | 744 | 279,258 | 110,787 | -367,248 | -367,279 | -406,907 | -319,050 | -824,596 | -669,760 | -465,921 | -543,112 |
| total shareholders funds | -294 | 744 | 279,258 | 110,787 | -367,248 | -367,279 | -406,907 | -319,050 | -824,596 | -669,760 | -465,921 | -543,112 |
| May 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | Sep 2015 | Sep 2014 | Sep 2013 | Sep 2012 | Sep 2011 | Sep 2010 | Sep 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | ||||||||||||
| Depreciation | 196 | 371 | 802 | 607 | 462 | 575 | 1,184 | 1,413 | 690 | |||
| Amortisation | ||||||||||||
| Tax | ||||||||||||
| Stock | ||||||||||||
| Debtors | -145,000 | 145,000 | -3,888 | -85,297 | 48,926 | -5,338 | 32,457 | -151,664 | -147,687 | 299,913 | 12,578 | |
| Creditors | -2,700 | 900 | -240 | -34,490 | -82,998 | -23,127 | 125,524 | -3,847 | -362,259 | 369,875 | 375 | 12,987 |
| Accruals and Deferred Income | 2,700 | |||||||||||
| Deferred Taxes & Provisions | ||||||||||||
| Cash flow from operations | ||||||||||||
| Investing Activities | ||||||||||||
| capital expenditure | ||||||||||||
| Change in Investments | -7,172 | -20,356 | 27,528 | |||||||||
| cash flow from investments | ||||||||||||
| Financing Activities | ||||||||||||
| Bank loans | ||||||||||||
| Group/Directors Accounts | ||||||||||||
| Other Short Term Loans | ||||||||||||
| Long term loans | -365,868 | 4,953 | -13 | 360,928 | ||||||||
| Hire Purchase and Lease Commitments | ||||||||||||
| other long term liabilities | -360,915 | -496,490 | 396,369 | -339,205 | 158,566 | 641,675 | ||||||
| share issue | ||||||||||||
| interest | ||||||||||||
| cash flow from financing | ||||||||||||
| cash and cash equivalents | ||||||||||||
| cash | -1,038 | -132,614 | 30,403 | 102,117 | -19,874 | -32,225 | 43,101 | -28,080 | 31,513 | -24,298 | -63,864 | 97,265 |
| overdraft | ||||||||||||
| change in cash | -1,038 | -132,614 | 30,403 | 102,117 | -19,874 | -32,225 | 43,101 | -28,080 | 31,513 | -24,298 | -63,864 | 97,265 |
pharmacogenomic innovative solutions limited Credit Report and Business Information
Pharmacogenomic Innovative Solutions Limited Competitor Analysis
Perform a competitor analysis for pharmacogenomic innovative solutions limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other undefined companies, companies in HP10 area or any other competitors across 12 key performance metrics.
pharmacogenomic innovative solutions limited Ownership
PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED group structure
Pharmacogenomic Innovative Solutions Limited has no subsidiary companies.
Ultimate parent company
CYTOPATHFINDER INC
#0068377
1 parent
PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED
06242578
pharmacogenomic innovative solutions limited directors
Pharmacogenomic Innovative Solutions Limited currently has 2 directors. The longest serving directors include Mr Alun McCarthy (May 2007) and Mr Ryuji Yamamoto (Apr 2011).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Alun McCarthy | England | 69 years | May 2007 | - | Director |
| Mr Ryuji Yamamoto | England | 83 years | Apr 2011 | - | Director |
P&L
May 2020turnover
0
-100%
operating profit
-1k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
May 2020net assets
-294
-1.4%
total assets
2.4k
-0.3%
cash
2.4k
-0.3%
net assets
Total assets minus all liabilities
pharmacogenomic innovative solutions limited company details
company number
06242578
Type
Private limited with Share Capital
industry
70229 - Management consultancy activities (other than financial management)
incorporation date
May 2007
age
18
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
May 2020
previous names
N/A
accountant
KNIGHT & CO
auditor
-
address
grove house, grove house, manor close, high wycombe, buckinghamshire, HP10 8HZ
Bank
-
Legal Advisor
-
pharmacogenomic innovative solutions limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pharmacogenomic innovative solutions limited.
pharmacogenomic innovative solutions limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHARMACOGENOMIC INNOVATIVE SOLUTIONS LIMITED. This can take several minutes, an email will notify you when this has completed.
pharmacogenomic innovative solutions limited Companies House Filings - See Documents
| date | description | view/download |
|---|
